Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...

Thermo Fisher Scientific is starting 2026's J.P. Morgan Healthcare Conference with a bang, announcing two new deals with an ...

The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026 ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

After a six-month battle, Edwards Lifesciences has been forced to walk away from its nearly $1 billion takeover attempt of ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro ...

Boston Scientific is buying up privately owned medtech Valencia Technologies for its implantable device aimed at helping ...

| Servier is committing to rare neurology for the long term, using focused science and strategic collaborations to bring new ...

Bayer, looking to bolster its position in both imaging and cardiac medicine, struck a deal to snap up two experimental imaging agents and thereby enter the diagnostic tracers development space. | ...

AbbVie has made no secret of the fact that it’s taken an interest in the hotly contested PD-1xVEGF bispecific space. | AbbVie has made no secret of the fact that it's taken an interest in the hotly ...

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices.